U
ELOS

UBS’s Syneron Medical Ltd ELOS Stock Holding History

UBS’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,626
Closed -$27K – 11076
2014
Q2 		$27K Buy
2,626
+27
+1% +$292 ﹤0.01% 7708
2014
Q1 		$33K Sell
2,599
-1,251
-32% -$14.8K ﹤0.01% 7416
2013
Q4 		$47K Sell
3,850
-1,100
-22% -$11.4K ﹤0.01% 7041
2013
Q3 		$43K Buy
4,950
+100
+2% +$863 ﹤0.01% 7074
2013
Q2 		$42K Buy
+4,850
New +$43.4K ﹤0.01% 6969

Other funds holding ELOS

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HC
Hourglass Capital Houston, Texas $454M AUM 32.9% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

UBS's ELOS Position: Q3 2014 in Review

UBS sold out of Syneron Medical Ltd (ELOS) in Q3 2014, closing a stake of 2,626 shares — an estimated $27K sold.

UBS first reported a position in ELOS in Q2 2013 and held it in 5 quarters. The position peaked at $47K in Q4 2013. 65 funds tracked by Wall St. Rank hold ELOS as of Q3 2014.

  • UBS reported no remaining Syneron Medical Ltd position as of Q3 2014 after selling out during the quarter.
  • UBS sold 2,626 Syneron Medical Ltd shares in Q3 2014, an estimated $27K.
  • UBS first reported a position in Syneron Medical Ltd in Q2 2013 and held it in 5 quarters.
  • UBS's Syneron Medical Ltd position peaked at $47K in Q4 2013.
  • 65 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.